Abstract Background: The impact of clonal haematopoiesis of indeterminate potential (CHIP), a novel cardiovascular risk factor, remains unclear in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), where cardiovascular disease (CVD) is the main cause of mortality. Methods: We analysed data from 140,086 UK Biobank participants with MASLD. CHIP was identified via whole-exome sequencing.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile